ARZERRA (ofatumumab)
CHRONIC LYMPHOCYTIC LEUKEMIA·+2
GSK
Indication
Relapsed chronic lymphocytic leukemia
Relapsed chronic lymphocytic leukemia is a hematologic malignancy characterized by the recurrence or progression of clonal B-cell proliferation following a prior complete or partial response to therapy, typically after a disease-free interval of at least six months. Read more about Relapsed chronic lymphocytic leukemia
4 drugs 4 manufacturers
Drugs that treat it
Common Relapsed chronic lymphocytic leukemia therapies.
ZYDELIG (idelalisib)
ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
GILEAD SCIENCES
ARZERRA (ofatumumab)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES·CHRONIC LYMPHOCYTIC LEUKEMIA·+2
Novartis Pharmaceuticals
ARZERRA (ofatumumab)
ANTINEOPLASTIC MONOCLONAL ANTIBODIES·CHRONIC LYMPHOCYTIC LEUKEMIA·+2
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Relapsed chronic lymphocytic leukemia preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRelapsed chronic lymphocytic leukemia is a hematologic malignancy characterized by the recurrence or progression of clonal B-cell proliferation following a prior complete or partial response to therapy, typically after a disease-free interval of at least six months.
Primarily affecting older adults, this condition involves the hematologic and lymphatic systems, specifically targeting the peripheral blood, bone marrow, spleen, and lymph nodes.
Pathophysiologically, the disease is driven by the resurgence of malignant, mature-appearing CD5- and CD19-positive monoclonal B lymphocytes that evade apoptosis.
Clinical manifestations frequently include worsening absolute lymphocytosis, progressive lymphadenopathy, hepatosplenomegaly, constitutional symptoms, and secondary cytopenias resulting from bone marrow infiltration.
- nih.gov
Relapsed chronic lymphocytic leukemia is a hematologic malignancy characterized by the recurrence or progression of clonal B-cell proliferation following a prior complete or partial response to therapy, typically after a disease-free interval of at least six months
- nih.gov
Relapsed chronic lymphocytic leukemia is a hematologic malignancy characterized by the recurrence or progression of clonal B-cell proliferation following a prior complete or partial response to therapy, typically after a disease-free interval of at least six months
- copiktra.com
Primarily affecting older adults, this condition involves the hematologic and lymphatic systems, specifically targeting the peripheral blood, bone marrow, spleen, and lymph nodes Pathophysiologically, the disease is driven by the resurgence of malignant, mature-appearing CD5- and CD19-positive monoclonal B lymphocytes that evade apoptosis
Personalize your experience
Follow Relapsed chronic lymphocytic leukemia and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.